William Blair Issues Pessimistic Outlook for OPCH Earnings

Option Care Health, Inc. (NASDAQ:OPCH) – Analysts at William Blair reduced their Q4 2024 earnings per share estimates for Option Care Health in a report released on Thursday, October 31st. William Blair analyst M. Larew now expects that the company will earn $0.30 per share for the quarter, down from their prior forecast of $0.35. The consensus estimate for Option Care Health’s current full-year earnings is $1.23 per share. William Blair also issued estimates for Option Care Health’s Q1 2025 earnings at $0.24 EPS, Q2 2025 earnings at $0.30 EPS and Q3 2025 earnings at $0.35 EPS.

Option Care Health (NASDAQ:OPCH) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.05. Option Care Health had a return on equity of 15.30% and a net margin of 4.37%. The company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.22 billion.

A number of other research analysts also recently issued reports on the stock. JMP Securities boosted their target price on shares of Option Care Health from $36.00 to $37.00 and gave the company a “market outperform” rating in a research report on Monday, September 30th. Jefferies Financial Group downgraded Option Care Health from a “buy” rating to a “hold” rating and decreased their price target for the stock from $38.00 to $26.00 in a report on Thursday. Truist Financial lowered their price target on Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a research report on Friday. Bank of America downgraded shares of Option Care Health from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $43.00 to $29.00 in a report on Wednesday. Finally, Barrington Research dropped their price target on shares of Option Care Health from $40.00 to $32.00 and set an “outperform” rating on the stock in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Option Care Health presently has a consensus rating of “Moderate Buy” and an average price target of $31.60.

Option Care Health Price Performance

Shares of NASDAQ OPCH opened at $24.11 on Friday. The company has a market capitalization of $4.10 billion, a PE ratio of 20.26, a P/E/G ratio of 1.74 and a beta of 1.32. The company has a quick ratio of 1.36, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. Option Care Health has a twelve month low of $22.84 and a twelve month high of $34.63. The firm has a fifty day simple moving average of $30.49 and a 200 day simple moving average of $29.91.

Insider Buying and Selling at Option Care Health

In other Option Care Health news, Director Elizabeth Quadros Betten sold 47,531 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $31.09, for a total value of $1,477,738.79. Following the completion of the sale, the director now owns 21,339 shares in the company, valued at approximately $663,429.51. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Elizabeth Quadros Betten sold 47,531 shares of Option Care Health stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $31.09, for a total transaction of $1,477,738.79. Following the sale, the director now owns 21,339 shares of the company’s stock, valued at approximately $663,429.51. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Michael H. Shapiro sold 23,217 shares of the stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.95, for a total transaction of $718,566.15. Following the completion of the transaction, the chief financial officer now directly owns 247,317 shares of the company’s stock, valued at approximately $7,654,461.15. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.64% of the company’s stock.

Institutional Trading of Option Care Health

Institutional investors have recently added to or reduced their stakes in the business. UMB Bank n.a. lifted its holdings in Option Care Health by 937.5% during the third quarter. UMB Bank n.a. now owns 830 shares of the company’s stock valued at $26,000 after purchasing an additional 750 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Option Care Health by 110.6% during the 3rd quarter. GAMMA Investing LLC now owns 897 shares of the company’s stock valued at $28,000 after purchasing an additional 471 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in Option Care Health by 3,362.8% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 1,489 shares of the company’s stock valued at $47,000 after buying an additional 1,446 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Option Care Health by 14.8% in the second quarter. Blue Trust Inc. now owns 2,931 shares of the company’s stock valued at $81,000 after purchasing an additional 377 shares in the last quarter. Finally, SageView Advisory Group LLC purchased a new stake in Option Care Health during the first quarter valued at $85,000. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.